Perspectives for a vaccine against hepatitis delta virus

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis delta virus (HDV) coinfection with hepatitis B virus (HBV) leads to severe liver disease, including cirrhosis and liver carcinoma, affecting ~15 million globally.
• Specific immune response defects driving HDV persistence remain unidentified.
• Previous vaccine development efforts in preclinical models have largely failed.

Purpose of the Study:

• To evaluate the efficacy of a DNA prime and viral vector boost immunization strategy in inducing a protective immune response against HDV.
• To assess the potential of this strategy for preventing HDV superinfection in chronic HBV carriers.

Main Methods:

• Utilized a preclinical woodchuck model of simultaneous woodchuck hepatitis virus-HDV infection.
• Administered a DNA prime followed by a viral vector boost immunization regimen.
• Assessed the induction of HDV-specific CD8 T cell responses and protection against HDV infection and replication.

Main Results:

• The DNA prime and viral vector boost immunization successfully induced HDV-specific CD8 T cell responses in the preclinical model.
• This immune response was effective in preventing HDV replication and spread in the liver during simultaneous infection.
• However, the induced T-cell response appears insufficient to prevent HDV spread in chronic HBV carriers, particularly for genotype-1.

Conclusions:

• A DNA prime and viral vector boost immunization can elicit a protective CD8 T cell response against HDV in a preclinical model.
• Current vaccine strategies may not be sufficient to prevent HDV superinfection in individuals with chronic HBV infection.
• More potent vaccines and potentially repeated vaccinations are required to achieve effective prevention of HDV superinfection in HBsAg carriers.